Form 4: Compass Therapeutics CEO Sells Shares for Tax Obligations

Compass Therapeutics CEO Thomas J. Schuetz disposed of 36,687 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Thomas J. Schuetz, CEO and Director of Compass Therapeutics, Inc. (CMPX), reported a transaction involving company common stock.
• On February 8, 2026, Mr. Schuetz disposed of 36,687 shares of common stock at a price of $6.52 per share.
• This disposal was solely to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following this transaction, Mr. Schuetz beneficially owns 6,603,336 shares of common stock.
• His beneficial ownership includes 125,000 unvested RSUs granted on February 8, 2023, vesting in four equal annual installments, with the first installment vested on February 8, 2024.
• It also includes 318,750 unvested RSUs granted on January 9, 2024, vesting in four equal annual installments, with the first installment vested on January 9, 2025.
• Additionally, 250,000 unvested RSUs granted on January 2, 2026, are included, vesting in four equal annual installments, with the first installment vested on January 2, 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While shares were disposed, it was for tax purposes related to RSU vesting, which is a positive compensation event for the executive and indicates continued alignment with company performance.

Positives

• The transaction indicates the vesting of restricted stock units, which is a form of executive compensation and retention.
• The CEO continues to hold a substantial beneficial ownership of 6,603,336 shares, aligning his interests with shareholders.

Negatives

• The disposal of shares, even for tax purposes, reduces the direct shareholding of the CEO.

Future Outlook

The filing details future vesting schedules for restricted stock units, indicating ongoing service-based compensation for the CEO through at least January 2, 2027.

Management Comments

• Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

Industry Context

StockSavvy.ai notes that routine insider transactions, such as share disposals for tax withholding related to RSU vesting, are common practice in executive compensation across various industries, particularly in biotechnology and pharmaceuticals where long-term incentives are prevalent. This transaction does not indicate a shift in broader industry trends but rather a standard operational aspect of executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact. The transaction is a routine part of executive compensation. The CEO's continued substantial beneficial ownership aligns interests.
• Management: The CEO receives vested equity, which is a positive for his compensation.

Next Steps

• Continued vesting of 125,000 RSUs granted on February 8, 2023, in subsequent annual installments after February 8, 2024.
• Continued vesting of 318,750 RSUs granted on January 9, 2024, in subsequent annual installments after January 9, 2025.
• Continued vesting of 250,000 RSUs granted on January 2, 2026, in subsequent annual installments after January 2, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO disposed of shares to cover tax obligations related to RSU vesting. Such transactions are expected and do not typically signal a change in the company's fundamentals or the executive's confidence. The CEO retains a significant beneficial ownership, which is a positive for alignment. Without additional information on company performance or strategic developments, the filing alone does not warrant a change from a 'hold' position.

Keywords

Compass Therapeutics, CMPX, Thomas J. Schuetz, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership, CEO, Director